These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20194810)

  • 21. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
    Reesink HJ; van der Plas MN; Verhey NE; van Steenwijk RP; Kloek JJ; Bresser P
    J Thorac Cardiovasc Surg; 2007 Feb; 133(2):510-6. PubMed ID: 17258590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension.
    Montani D; Souza R; Binkert C; Fischli W; Simonneau G; Clozel M; Humbert M
    Chest; 2007 Jan; 131(1):101-8. PubMed ID: 17218562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension.
    Douwes JM; Roofthooft MT; Bartelds B; Talsma MD; Hillege HL; Berger RM
    Int J Cardiol; 2013 Sep; 168(2):1370-7. PubMed ID: 23340486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving ≤2 years and those surviving ≥5 years after baseline right-sided cardiac catheterization.
    Batal O; Khatib OF; Dweik RA; Hammel JP; McCarthy K; Minai OA
    Am J Cardiol; 2012 May; 109(10):1514-20. PubMed ID: 22360818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary arterial dilatation in pulmonary hypertension: prevalence and prognostic relevance.
    Badagliacca R; Poscia R; Pezzuto B; Papa S; Nona A; Mancone M; Mezzapesa M; Nocioni M; Sciomer S; Valli G; Cedrone N; Fedele F; Vizza CD
    Cardiology; 2012; 121(2):76-82. PubMed ID: 22433455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure.
    Grigioni F; Potena L; Galiè N; Fallani F; Bigliardi M; Coccolo F; Magnani G; Manes A; Barbieri A; Fucili A; Magelli C; Branzi A
    J Heart Lung Transplant; 2006 Oct; 25(10):1241-6. PubMed ID: 17045937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resting sympathetic outflow does not predict the morning blood pressure surge in hypertension.
    Hering D; Kucharska W; Kara T; Somers VK; Narkiewicz K
    J Hypertens; 2011 Dec; 29(12):2381-6. PubMed ID: 21986622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension.
    Blumberg FC; Arzt M; Lange T; Schroll S; Pfeifer M; Wensel R
    Eur J Heart Fail; 2013 Jul; 15(7):771-5. PubMed ID: 23507788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Value of Pericardial Effusion on Serial Echocardiograms in Pulmonary Arterial Hypertension.
    Batal O; Dardari Z; Costabile C; Gorcsan J; Arena VC; Mathier MA
    Echocardiography; 2015 Oct; 32(10):1471-6. PubMed ID: 25682779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Muscle sympathetic nerve activity in patients with Chagas' disease.
    Negrão CE; Santos AC; Rondon MU; Franco FG; Ianni B; Rochitte CE; Braga AM; Oliveira MT; Mady C; Barretto AC; Middlekauff HR
    Int J Cardiol; 2009 Nov; 137(3):252-9. PubMed ID: 18723231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
    Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
    Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relation of resting heart rate to prognosis in patients with idiopathic pulmonary arterial hypertension.
    Henkens IR; Van Wolferen SA; Gan CT; Boonstra A; Swenne CA; Twisk JW; Kamp O; van der Wall EE; Schalij MJ; Vonk-Noordegraaf A; Vliegen HW
    Am J Cardiol; 2009 May; 103(10):1451-6. PubMed ID: 19427445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
    Garg N; Sharma MK; Sinha N
    Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension.
    Nickel N; Kempf T; Tapken H; Tongers J; Laenger F; Lehmann U; Golpon H; Olsson K; Wilkins MR; Gibbs JS; Hoeper MM; Wollert KC
    Am J Respir Crit Care Med; 2008 Sep; 178(5):534-41. PubMed ID: 18565955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.
    Farber HW; Miller DP; Meltzer LA; McGoon MD
    J Heart Lung Transplant; 2013 Nov; 32(11):1114-22. PubMed ID: 24035189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.
    Damico R; Kolb TM; Valera L; Wang L; Housten T; Tedford RJ; Kass DA; Rafaels N; Gao L; Barnes KC; Benza RL; Rand JL; Hamid R; Loyd JE; Robbins IM; Hemnes AR; Chung WK; Austin ED; Drummond MB; Mathai SC; Hassoun PM
    Am J Respir Crit Care Med; 2015 Jan; 191(2):208-18. PubMed ID: 25489667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.